However, G3BP1 also suppresses migration in an mTORC1-dependent manner (Prentzell et al., 2021; Figure 1), suggesting that targeting G3BP1 may be contraindicated in some situations, such as breast cancer, in which lower levels of G3BP1, TSC1, and TSC2 are associated with reduced relapse-free survival (Prentzell et al., 2021). Here, TSC2 is linked to breast carcinoma.